Compare SNGX & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | ACON |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 7.4M |
| IPO Year | 2006 | 2022 |
| Metric | SNGX | ACON |
|---|---|---|
| Price | $0.37 | $2.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 205.9K | 61.1K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.03 | ★ 99.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,371.00 | $75,730.00 |
| Revenue This Year | N/A | $87.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.62 |
| 52 Week Low | $0.28 | $1.95 |
| 52 Week High | $2.98 | $12.03 |
| Indicator | SNGX | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 52.86 |
| Support Level | $0.36 | $2.33 |
| Resistance Level | $0.42 | $3.54 |
| Average True Range (ATR) | 0.02 | 0.15 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 7.46 | 46.55 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.